Skip to content

UTHR

Current
Price
$554.73
Discount category
Close to intrinsic value
Intrinsic value source
AI estimate
Next earnings
Feb 4, 2027
Next earnings is estimate
Yes
Company name
United Therapeutics
Sector
Biotechnology: medicines for pulmonary hypertension and lung disease
About
United Therapeutics Corporation (UTHR) is a US biotechnology company and a public benefit corporation. It sells treprostinil medicines for pulmonary arterial hypertension (PAH) and for pulmonary hypertension with interstitial lung disease (PH-ILD): Tyvaso DPI and nebulized Tyvaso, which patients inhale, Remodulin, which is an infusion, and Orenitram, which is a tablet. It also sells Unituxin for a cancer in children. It develops ralinepag, an oral medicine for PAH, and manufactured organs and organ alternatives for transplant. Revenue was $2,397.3 million in the first nine months of 2026, and Tyvaso products gave 61% of Q3 revenue. Two US distributors gave 50% and 40% of Q3 revenue. United Therapeutics has no debt.
Thesis
The price of United Therapeutics depends on whether new uses and new medicines can replace treprostinil sales that face more competition. Yutrepia from Liquidia competes with Tyvaso, nebulized Tyvaso sales fell 12% in Q3 2026, and generic Orenitram can start from June 2027. Investors also doubt that the large spending on manufactured organs will earn a return. For the AI estimate to be right, three things must be true. The FDA must approve nebulized Tyvaso for idiopathic pulmonary fibrosis (IPF) by its goal date of April 26, 2027, and sales in IPF must grow. The FDA must approve ralinepag by its goal date of June 24, 2027, although it found problems at the plant that makes the active ingredient. Tyvaso DPI must keep growing after Liquidia stops selling Yutrepia for PH-ILD. The Q4 2026 report, expected in early February 2027, and the two FDA decisions in 2027 are the tests. If either approval is late, sales growth can stop in 2027.
Valuation
The intrinsic value for United Therapeutics is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the filings of United Therapeutics with the SEC. The method is a multiple of 2027 operating income after tax, plus net cash, divided by the diluted share count. The Q3 2026 release (8-K, November 4, 2026) gives revenue of $832.5 million and net income of $258.6 million for Q3, and cash, cash equivalents and marketable investments of $3,535.7 million at September 30, 2026. The Form 10-Q for the quarter ended September 30, 2026 gives revenue of $2,397.3 million and net income of $866.5 million for nine months. This net income includes an expense of $133.6 million for the purchase of Thymmune and the reversal of a litigation accrual of $66.5 million. The 10-K for 2025 gives net income of $1,334.7 million and diluted EPS of $27.86 for 2025. The 10-Q says that United Therapeutics has no borrowings under its $2.5 billion credit facility. It also says that the company received $185.0 million from Liquidia in October 2026, that Liquidia must pay $145.4 million more in the first half of 2027, that the company paid $10.0 million to settle the Sandoz case and that it paid $525.0 million to Arena on November 3, 2026 to end the royalties on ralinepag. The estimate adds these amounts to the cash, so net cash is $3,331.1 million. The cover of the 10-Q gives 42,588,726 shares of common stock at October 28, 2026. The estimate adds 2.6 million shares for stock options and restricted stock units, which is the difference between the diluted and basic weighted share counts of Q3 2026 in the release, so it uses 45.19 million shares. It does not subtract the shares that the September 2026 accelerated share repurchase can still deliver. The 2027 operating income after tax and the multiples are assumptions. The low case assumes $1,050 million, because generic Orenitram from June 2027 and Yutrepia reduce sales and the FDA decisions come late, at 13 times. It gives $375.78 per share. The base case assumes $1,300 million, with approval of nebulized Tyvaso for IPF in April 2027 and of ralinepag in June 2027, at 16 times. It gives $534.01 per share. The high case assumes $1,600 million, with a fast start of Tyvaso in IPF, at 19 times. It gives $746.45 per share. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $547.56 per share. As of Nov 14, 2026.
Risks
Treprostinil products face more competition. Yutrepia competes with Tyvaso DPI and nebulized Tyvaso, and doctors can still use it off-label for PH-ILD. Watson can sell generic nebulized Tyvaso when the FDA approves it, and Actavis and ANI can sell generic Orenitram from June 2027 and December 2027. In late September 2026, the FDA classified an inspection of the ScinoPharm plant that makes the active ingredient of ralinepag as Official Action Indicated. If the plant is not compliant in time, the FDA can refuse to approve ralinepag by June 2027. The FDA can reject or delay the application for nebulized Tyvaso in IPF, which is the largest new market of the company. Two distributors gave 50% and 40% of Q3 2026 revenue. A problem with one of them can reduce sales for a time. The company spends a lot on research, manufactured organs and new plants: research and development expense was $563.7 million and capital expenditure was $389.5 million in the first nine months of 2026. These programs can take many years to earn revenue.
Balance sheet
Cash: $3.5B Debt: $0.0M Net cash: $3.5B At September 30, 2026, United Therapeutics had cash and cash equivalents of $1,188.9 million and marketable investments of $2,346.8 million, a total of $3,535.7 million. It had no borrowings under its $2.5 billion unsecured revolving credit facility, which matures in 2031. Total liabilities were $758.1 million. Cash and investments fell from $4,697.0 million at December 31, 2025, mainly because the company bought back shares for about $1.9 billion in 2026. Net cash from operating activities was $1,083.4 million in the first nine months of 2026. In October 2026, the company received $185.0 million from Liquidia, and Liquidia must pay $145.4 million more in the first half of 2027. On November 3, 2026, the company paid $525.0 million to Arena from cash on hand. As of Sep 30, 2026.
Checkpoints
Feb 4, 2027 (estimate): Q4 2026 results. Pending. Watch: Tyvaso DPI revenue keeps growing year over year after the Liquidia settlement, and this passes; a fall in total Tyvaso revenue fails. Apr 26, 2027: FDA decision on nebulized Tyvaso for IPF. Pending. Watch: The FDA approves nebulized Tyvaso for IPF by its goal date, and this passes; a complete response letter or a delay fails. Jun 24, 2027: FDA decision on ralinepag for PAH. Pending. Watch: The FDA approves ralinepag extended-release tablets by its goal date, and this passes; a complete response letter, for example because of the ScinoPharm plant, fails.
Recent events
Nov 4, 2026: United Therapeutics reported Q3 2026 results. Revenue grew 4% to $832.5 million. Tyvaso DPI revenue grew 13% to $378.5 million, and nebulized Tyvaso revenue fell 12% to $125.3 million. Net income was $258.6 million, after an expense of $133.6 million for the purchase of Thymmune. Nov 3, 2026: United Therapeutics paid $525.0 million to Arena, a subsidiary of Pfizer, to end its obligation to pay royalties on future sales of ralinepag. It expects an expense of $525.0 million in Q4 2026. Oct 22, 2026: The board approved a new share repurchase program of up to $2 billion, available through October 21, 2027. Oct 13, 2026: United Therapeutics settled its patent case with Liquidia, after a court ruled on September 30, 2026 that Yutrepia infringes its PH-ILD patent. Liquidia agreed to pay $330.4 million, to stop promoting Yutrepia for PH-ILD and to remove PH-ILD from the Yutrepia label. United Therapeutics paid $10.0 million to settle the Sandoz case. Sep 8, 2026: United Therapeutics started an accelerated share repurchase of about $477.6 million, which used the rest of its $2 billion authorization of March 2026. Jul 1, 2026: United Therapeutics bought Thymmune Therapeutics, which develops thymic cell therapies, for about $140.0 million in cash and up to $160.0 million in milestone payments. Mar 30, 2026: The TETON-1 study of nebulized Tyvaso in IPF met its main goal, with a difference of 130.1 mL in forced vital capacity against placebo. The FDA later accepted the application for IPF, with a goal date of April 26, 2027. Mar 2, 2026: The phase 3 ADVANCE OUTCOMES study of ralinepag in PAH met its main goal and reduced the risk of clinical worsening by 55% against placebo. The FDA later accepted the application, with a goal date of June 24, 2027.
See changes